Profile data is unavailable for this security.
About the company
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
- Revenue in USD (TTM)0.00
- Net income in USD-11.25m
- Incorporated2021
- Employees--
- LocationTelomir Pharmaceuticals Inc900 West Platt Street, Suite 200TAMPA 33606United StatesUSA
- Phone+1 (813) 864-2562
- Websitehttps://telomirpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | TELO:NAQ since announced | Transaction value |
|---|---|---|
| TELI Pharmaceuticals Inc | -34.34% | -- |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TherapeuticsMD Inc | 2.80m | 73.00k | 27.32m | 1.00 | 378.21 | 0.9953 | 59.38 | 9.77 | 0.0062 | 0.0261 | 0.2419 | 2.37 | 0.0715 | -- | 0.8002 | 2,796,000.00 | 0.1867 | -42.65 | 0.2169 | -112.14 | -- | -- | 2.61 | -193.47 | -- | -5,240.00 | 0.00 | -- | 35.25 | -48.72 | 69.97 | -- | -- | -- |
| Kyntra Bio Inc | 8.30m | -131.13m | 30.14m | 225.00 | -- | -- | -- | 3.63 | -32.49 | 53.34 | 2.05 | -4.21 | 0.0413 | -1.47 | 0.421 | 36,880.00 | -64.00 | -39.47 | -260.98 | -61.33 | 345.69 | 90.21 | -1,548.18 | -199.02 | 3.60 | -- | 0.5269 | -- | -36.71 | -35.07 | 52.60 | -- | -45.94 | -- |
| United-Guardian Inc | 10.06m | 1.96m | 30.32m | 24.00 | 15.47 | 2.87 | 14.69 | 3.01 | 0.4266 | 0.4266 | 2.19 | 2.30 | 0.7911 | 3.82 | 7.58 | 419,180.40 | 15.41 | 26.91 | 17.85 | 31.16 | 50.60 | 54.16 | 19.48 | 26.97 | 6.16 | -- | 0.00 | 92.34 | 11.91 | -2.18 | 25.94 | -7.35 | 30.65 | -8.64 |
| SCYNEXIS Inc | 2.93m | -25.30m | 31.47m | 28.00 | -- | 0.8638 | -- | 10.73 | -0.5107 | -0.5107 | 0.0593 | 0.8683 | 0.0391 | -- | 0.5776 | 104,714.30 | -33.71 | -20.51 | -43.65 | -24.97 | 33.32 | -- | -862.89 | -64.82 | -- | -- | 0.00 | -- | -97.33 | 98.68 | -131.75 | -- | -- | -- |
| Healthy Extracts Inc | 3.59m | -1.17m | 33.74m | 2.00 | -- | 1.40 | -- | 9.40 | -0.3195 | -0.3195 | 0.9095 | 1.43 | 0.2505 | 1.42 | 140.67 | 1,794,555.00 | -8.19 | -61.21 | -9.09 | -111.60 | 52.37 | 51.30 | -32.71 | -82.01 | 0.6491 | -2.84 | 0.0421 | -- | 25.24 | 32.99 | 66.01 | -- | -- | -- |
| BioXcel Therapeutics Inc | 752.00k | -68.21m | 34.55m | 37.00 | -- | -- | -- | 45.95 | -10.41 | -10.41 | 0.1023 | -4.45 | 0.016 | 0.9718 | 501.33 | 20,324.32 | -145.62 | -76.45 | -449.90 | -88.28 | -28.19 | -- | -9,070.61 | -14,760.23 | 1.16 | -3.25 | 5.40 | -- | 64.20 | -- | 66.71 | -- | -- | -- |
| Hyperion DeFi Inc | 345.32k | -26.40m | 35.08m | 13.00 | -- | 0.4191 | -- | 101.58 | -20.32 | -20.32 | 0.0385 | 9.88 | 0.0065 | -- | 1.06 | 26,563.08 | -48.31 | -102.28 | -59.47 | -168.53 | -798.11 | 60.58 | -7,385.51 | -856.97 | -- | -- | 0.0976 | -- | 1,412.93 | -- | -82.75 | -- | -0.6271 | -- |
| Celularity Inc | 40.58m | -80.71m | 36.48m | 123.00 | -- | -- | -- | 0.899 | -3.34 | -3.34 | 1.69 | -0.7121 | 0.3339 | 6.14 | 5.24 | 329,902.40 | -66.35 | -23.42 | -158.76 | -26.83 | 50.61 | -- | -198.75 | -294.70 | 0.123 | -6.57 | 2.01 | -- | 138.11 | -- | 70.51 | -- | -- | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -11.25m | 37.48m | -- | -- | 5.28 | -- | -- | -0.3739 | -0.3739 | 0.00 | 0.2063 | 0.00 | -- | -- | -- | -266.47 | -- | -303.19 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.48 | -- | -- | -- |
| Talphera Inc | 28.00k | -12.46m | 37.79m | 13.00 | -- | 1.93 | -- | 1,349.68 | -0.3808 | -0.378 | 0.0009 | 0.4207 | 0.0011 | -- | -- | 2,153.85 | -48.15 | -14.86 | -54.44 | -19.40 | -- | -- | -44,503.57 | -446.19 | -- | -- | 0.00 | -- | -100.00 | -- | -26.41 | -- | -- | -- |
| Earth Science Tech Inc | 33.84m | 2.81m | 38.01m | 76.00 | 14.08 | 7.61 | 12.30 | 1.12 | 0.0092 | 0.0092 | 0.1114 | 0.0171 | 4.93 | 12.73 | 156.99 | 445,269.50 | 40.56 | 24.04 | 66.31 | -- | 72.21 | 71.08 | 8.22 | 5.50 | 0.7202 | 7.06 | 0.009 | -- | 177.05 | 128.98 | 300.63 | -- | -- | -- |
| Rockwell Medical Inc | 75.58m | -5.48m | 39.80m | 244.00 | -- | 1.08 | -- | 0.5266 | -0.1583 | -0.1583 | 2.20 | 0.9395 | 1.32 | 12.92 | 8.78 | 309,741.80 | -9.63 | -32.92 | -12.15 | -46.61 | 15.81 | 8.00 | -7.30 | -23.86 | 3.50 | -6.13 | 0.2141 | -- | 21.38 | 10.61 | 94.31 | -- | 11.47 | -- |
| BioScience Health Innovations Inc | 4.73m | 885.68k | 43.92m | -- | 206.50 | 25.67 | -- | 9.29 | 0.0194 | 0.0194 | 0.1313 | 0.1558 | 3.81 | 4.30 | 99.37 | -- | 71.34 | -- | 85.11 | -- | 63.64 | -- | 18.74 | -- | 3.47 | -- | 0.00 | -- | 208.73 | -- | 134.59 | -- | -- | -- |
| Elutia Inc | 21.08m | -22.99m | 44.84m | 51.00 | -- | -- | -- | 2.13 | -0.6006 | -0.6827 | 0.5347 | -1.03 | 0.5419 | 4.04 | 6.50 | 413,411.80 | -59.08 | -57.79 | -- | -128.41 | 45.97 | 42.77 | -109.03 | -92.86 | 0.396 | -- | -- | -- | -1.50 | -10.69 | -31.23 | -- | 2.54 | -- |
| Zhengye Biotechnology Holding Ltd | 22.25m | -2.80m | 45.54m | 277.00 | -- | 1.05 | 134.80 | 2.05 | -0.059 | -0.059 | 0.4787 | 0.9131 | 0.3099 | 1.62 | 2.04 | 80,341.63 | -4.60 | -- | -7.79 | -- | 37.37 | -- | -14.83 | -- | 1.10 | -7.00 | 0.1902 | -- | -11.95 | -- | -64.04 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Telomir Pharmaceuticals Inc's reporting currency: US Dollar USD
6.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 995.37k | 3.08% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 281.82k | 0.87% |
| Geode Capital Management LLCas of 31 Dec 2025 | 223.55k | 0.69% |
| Millennium Management LLCas of 30 Sep 2025 | 222.40k | 0.69% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 135.54k | 0.42% |
| Raymond James Financial Services Advisors, Inc.as of 30 Sep 2025 | 75.34k | 0.23% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 58.60k | 0.18% |
| The Bank of New York Mellon Corp. (Investment Management)as of 31 Dec 2025 | 51.45k | 0.16% |
| Suncoast Equity Management LLCas of 31 Dec 2025 | 51.19k | 0.16% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 41.84k | 0.13% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
